why choose us

First received: December 05, 2022

Clinical Trial: Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

Study Status: Completed

Recruit Status: RECRUITING

Condition: Skin Diseases

Study Type: INTERVENTIONAL


Official Title: Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders: a Single-Site Pilot Study

Brief Summary: Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life.The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to be Th2-driven; and b) the administration of dupilumab will be well-tolerated, regardless of underlying genetic skin disorder.The total clinical study duration will be 26 months (104 Weeks).The treatment period will…

Read more